1 / 35

Obesity in the end stage kidney disease population

Obesity in the end stage kidney disease population. Dr Maleeka Ladhani PhD Candidate, Sydney School of Public Health Prof Jonathan Craig, A/P Germaine Wong. Framework. 1) Prevalence of obesity in the incident and prevalent ESKD population 2) Access to transplantation for those with obesity.

deluna
Download Presentation

Obesity in the end stage kidney disease population

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Obesity in the end stage kidney disease population Dr Maleeka Ladhani PhD Candidate, Sydney School of Public Health Prof Jonathan Craig, A/P Germaine Wong

  2. Framework • 1) Prevalence of obesity in the incident and prevalent ESKD population • 2) Access to transplantationfor those with obesity

  3. Prevalence of obesity in ESKD

  4. 27% 19% Australian Institute of Health and Welfare 2015. Cardiovascular disease, diabetes and chronic kidney disease— Australian facts: Risk factors. Cardiovascular, diabetes and chronic kidney disease series no. 4. Cat. no. CDK 4. Canberra: AIHW.

  5. Aims • To describe the trends of obesity in the incident and prevalent Australian and New Zealand ESKD population, over time • Specifically stratifying by: • country • sex • age • diabetes status • modality of renal replacement

  6. Methods • All adult Australian and New Zealand patients • 1995 – 2014 • 49,884 patients (8,745 NZ - 32% Maori) • 286,500 observations over the whole period • BMI categorised according to WHO definition

  7. Obesity in incident RRT patients ieBMI at RRT initiation for all adult patients

  8. Australia and New Zealand

  9. Sex differences - Australia

  10. Sex differences – New Zealand

  11. AgeAust

  12. AgeNZ

  13. Diabetes -Australia

  14. Diabetes – New Zealand

  15. Modality – Australia

  16. Modality – New Zealand

  17. Obesity in prevalent patients ie all patients on RRT each year

  18. Australia and New Zealand

  19. Modality – Australia

  20. Modality – New Zealand

  21. Access to transplantation

  22. BMI association with all-cause mortality Ladhani et al, NDT 2016

  23. BMI association with all-cause mortality Ladhani et al, NDT 2016

  24. Chang et al Transplantation 2007

  25. Chang et al Transplantation 2007

  26. Aims • To examine access to transplantation for people with obesity in 3 ways • 1) Pre-emptive transplantation • 2) Time to first transplant • 3) Placement on the waiting list

  27. Methods • 1) Pre-emptive transplantation • Descriptive data limited to 2014 • 2) Time to first transplant • Kaplan Meier curve restricted to incident patients • <70 years, 1995-2014 • 3) Placement on the waiting list • Logistic regression limited to 2014 and patients <70 years with outcome of listed or not listed • Adjusted for relevant confounders +/- centre effect

  28. Pre-emptive transplantation

  29. Time to transplantation

  30. Baseline stats

  31. Baseline stats

  32. Centre effect modeled as a random intercept

  33. Conclusions • Obesity is increasingly common in the ESKD population • Despite evidence that long term patient and graft outcomes are not affected by obesity, people with obesity are: • less likely to start RRT with a transplant • less likely to receive a transplant over time • less likely to be on the waiting list for a transplant– despite adjusting for confounders

  34. Implications • There appears to be a discrepancy in access to transplantation for people with obesity that is not supported by long term outcome studies • This needs to be looked at further • Thank you to all ANZDATA contributors

More Related